Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.

Details

Ressource 1Download: cancers-14-04275.pdf (1800.96 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_62CF2A596AB9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Journal
Cancers
Author(s)
Adamina M., Warlaumont M., Berger M.D., Däster S., Delaloye R., Digklia A., Gloor B., Fritsch R., Koeberle D., Koessler T., Lehmann K., Müller P., Peterli R., Ris F., Steffen T., Weisshaupt C.S., Hübner M.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
01/09/2022
Peer-reviewed
Oui
Volume
14
Number
17
Pages
4275
Language
english
Notes
Publication types: Guideline
Publication Status: epublish
Abstract
Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival is possible. Complete cytoreductive surgery (CRS) together with combination immunochemotherapy is essential to achieve cure. Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are increasingly added to the multimodal treatment. The Swiss Peritoneal Cancer Group (SPCG) is an interdisciplinary group of expert clinicians. It has developed comprehensive treatment algorithms for patients with PC from pseudomyxoma peritonei, peritoneal mesothelioma, gastric, and colorectal origin. They include multimodal neoadjuvant treatment, surgical resection, and palliative care. The indication for and results of CRS HIPEC and PIPAC are discussed in light of the current literature. Institutional volume and clinical expertise required to achieve best outcomes are underlined, while inclusion of patients considered for CRS HIPEC and PIPAC in a clinical registry is strongly advised. The present recommendations are in line with current international guidelines and provide the first comprehensive treatment proposal for patients with PC including intraperitoneal chemotherapy. The SPCG comprehensive treatment algorithms provide evidence-based guidance for the multimodal care of patients with PC of gastrointestinal origin that were endorsed by all Swiss clinicians routinely involved in the multimodal care of these challenging patients.
Keywords
Cancer Research, Oncology, HIPEC, PIPAC, cytoreductive surgery, gastrointestinal cancer, hyperthermic intraperitoneal chemotherapy, peritoneal carcinomatosis, pressurized intraperitoneal chemotherapy
Pubmed
Web of science
Open Access
Yes
Create date
12/09/2022 9:39
Last modification date
21/11/2022 8:29
Usage data